BioSpace News Archive

Dewpoint’s drug platform targets biomolecular condensates, dynamic cellular structures newly understood to be central to many disease mechanisms

Correvio Pharma Corp., a specialty pharmaceutical company focused on commercializing hospital drugs, reported financial results for its third quarter ended September 30, 2019 and commented on recent accomplishments and plans..

Exicure to Receive $25 Million Upfront Payment and Up to $725 Million in potential Milestones

BELLUS Health Inc. reported its financial and operating results for the third quarter ended September 30, 2019.

Pure-Vu® System launched in high value U.S. inpatient colonoscopy market with first commercial placements at early adopter hospitals completed in early-October

Bicycle Therapeutics plc announced that management will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20, 2019 at 2:40 p.m. GMT in London, England.

BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), a clinical-stage biotechnology company focused patient-specific immunotherapies for the treatment of cancer and other serious diseases, today provided an update on its corporate progress and reported financial results for the quarter ended September 30, 2019.

VistaGen Therapeutics announced topline results from the ELEVATE study, a Phase 2 study of AV-101, its NMDA (N-methyl-D-aspartate) receptor glycine site antagonist, as an adjunctive treatment of major depressive disorder (MDD).

CymaBay Therapeutics, Inc. announced that management will participate in two investor conferences including the Stifel 2019 Healthcare Conference taking place November 19-20, 2019 in New York City and the Evercore ISI 2nd Annual HEALTHCONx Conference in Boston, MA – December 3-5, 2019.

Daré Bioscience, Inc., a leader in women’s health innovation, reported financial results for the quarter ended September 30, 2019 and provided a company update.